AUTHOR=Yin Shanye , Klaeger Susan , Chea Vipheaviny A. , Carulli Isabel P. , Rachimi Suzanna , Black Katharine E. , Filbin Michael , Hariri Lida P. , Knipe Rachel S. , Padera Robert F. , Stevens Jonathan D. , Lane William J. , Carr Steven A. , Wu Catherine J. , Kim Edy Yong , Keskin Derin B. TITLE=Integrated Immunopeptidomic and Proteomic Analysis of COVID-19 lung biopsies JOURNAL=Frontiers in Immunology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1269335 DOI=10.3389/fimmu.2023.1269335 ISSN=1664-3224 ABSTRACT=Introduction

Severe respiratory illness is the most prominent manifestation of patients infected with SARS-CoV-2, and yet the molecular mechanisms underlying severe lung disease in COVID-19 affected patients still require elucidation. Human leukocyte antigen class I (HLA-I) expression is crucial for antigen presentation and the host’s response to SARS-CoV-2.

Methods

To gain insights into the immune response and molecular pathways involved in severe lung disease, we performed immunopeptidomic and proteomic analyses of lung tissues recovered at four COVID-19 autopsy and six non-COVID-19 transplants.

Results

We found signals of tissue injury and regeneration in lung fibroblast and alveolar type I/II cells, resulting in the production of highly immunogenic self-antigens within the lungs of COVID-19 patients. We also identified immune activation of the M2c macrophage as the primary source of HLA-I presentation and immunogenicity in this context. Additionally, we identified 28 lung signatures that can serve as early plasma markers for predicting infection and severe COVID-19 disease. These protein signatures were predominantly expressed in macrophages and epithelial cells and were associated with complement and coagulation cascades.

Discussion

Our findings emphasize the significant role of macrophage-mediated immunity in the development of severe lung disease in COVID-19 patients.